This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nymox Reports On Symposium And Panel Discussion On NX-1207 At American Urological Association Annual Meeting

HASBROUCK HEIGHTS, N.J., May 6, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation on NX-1207 drug studies at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Diego, CA between 3:00 and 4:00 pm PDT on Sunday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH) and featured expert panel discussions on the new therapy. The Company is pleased to report that the pivotal U.S. Phase 3 trials of NX-1207 for BPH, NX02-0017 and NX02-0018, have now completed enrollment.

The symposium, "Clinical studies of NX-1207: Phase 3 Injectable for BPH (Phase 2 for Prostate Cancer)," was chaired by Ronald F. Tutrone Jr., MD, FACS of Towson, MD. The other panel members at the Symposium were Dr. Mohamed Bidair of San Diego CA, Dr. Susan J. Kalota of Tucson AZ, Dr. Franklin D. Gaylis of San Diego CA, Dr. Sheldon Freedman of Las Vegas NV, Dr. Eugene Dula of Tarzana CA, and Dr. Michael T. Gambla of Columbus OH.

According to Dr. Tutrone, "I will be excited to see the results from the Phase 3 trials. I feel that NX-1207 has the potential to be a game changer in BPH and to dramatically improve the quality of life for men that suffer from BPH."

Dr. Dula said that NX-1207 is "the most innocuous and quick therapy for BPH. It delivers the medicine where you need it."

Dr. Kalota said that in her experience "NX-1207 is easy to inject and well tolerated and frequently produces excellent results."

Dr. Bidair said that NX-1207 was "extremely well tolerated."  He added that it took "less time to perform the procedure than to get the patient ready on the table."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.27 0.00%
FB $101.00 0.00%
GOOG $684.12 0.00%
TSLA $143.67 0.00%
YHOO $27.10 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs